Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) – Investment analysts at Leerink Swann dropped their FY2017 earnings per share (EPS) estimates for shares of Alexion Pharmaceuticals in a research note issued to investors on Monday. Leerink Swann analyst now expects that the biopharmaceutical company will post earnings per share of $5.16 for the year, down from their prior estimate of $5.17. Leerink Swann currently has a “Buy” rating and a $182.00 price target on the stock.

Several other equities research analysts have also recently weighed in on ALXN. Robert W. Baird reissued a “neutral” rating and set a $145.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, June 26th. UBS AG restated a “buy” rating and issued a $142.00 price objective (up from $140.00) on shares of Alexion Pharmaceuticals in a report on Monday, June 26th. Cowen and Company restated an “outperform” rating and issued a $122.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, July 3rd. SunTrust Banks, Inc. restated a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Friday, July 14th. Finally, TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a report on Friday, July 14th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $154.56.

WARNING: This story was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/10/19/fy2017-eps-estimates-for-alexion-pharmaceuticals-inc-alxn-reduced-by-analyst.html.

Alexion Pharmaceuticals (ALXN) traded down 0.14% during midday trading on Wednesday, reaching $140.05. 310,014 shares of the company’s stock traded hands. The company’s 50-day moving average price is $142.37 and its 200-day moving average price is $127.58. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34. The stock has a market cap of $31.26 billion, a P/E ratio of 60.73 and a beta of 1.39.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. During the same quarter last year, the firm earned $1.13 earnings per share. Alexion Pharmaceuticals’s quarterly revenue was up 21.1% on a year-over-year basis.

In related news, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now owns 5,480 shares in the company, valued at $799,038.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Julie O’neill sold 11,160 shares of the business’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares in the company, valued at approximately $3,738,560. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,190 shares of company stock worth $2,433,669. Company insiders own 4.35% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Guardian Life Insurance Co. of America increased its position in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 6 shares during the last quarter. Eqis Capital Management Inc. increased its position in Alexion Pharmaceuticals by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 6,776 shares of the biopharmaceutical company’s stock worth $824,000 after purchasing an additional 38 shares during the last quarter. Rathbone Brothers plc increased its position in Alexion Pharmaceuticals by 2.5% in the second quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 50 shares during the last quarter. Seven Bridges Advisors LLC increased its position in Alexion Pharmaceuticals by 2.1% in the second quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 53 shares during the last quarter. Finally, Geneva Advisors LLC increased its position in Alexion Pharmaceuticals by 0.7% in the second quarter. Geneva Advisors LLC now owns 11,408 shares of the biopharmaceutical company’s stock worth $1,388,000 after purchasing an additional 82 shares during the last quarter. Institutional investors own 94.25% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.